10-Q: ENDRA Life Sciences Reports Q2 2024 Results, Outlines Path to FDA Approval and Leadership Changes

ENDRA Life Sciences reported its second quarter 2024 results, highlighting ongoing efforts to secure FDA approval for its TAEUS system and announcing key leadership changes.

Summary

• ENDRA Life Sciences reported a net loss of $2.23 million for the three months ended June 30, 2024, and a net loss of $5.00 million for the six months ended June 30, 2024.
• The company had no revenue for the reported periods as it is still in the development and regulatory approval phase for its TAEUS technology.
• Research and development expenses decreased to $1.76 million for the six months ended June 30, 2024, compared to $2.79 million for the same period in 2023.
• The company completed a public offering in June 2024, raising net proceeds of $7.34 million.
• As of June 30, 2024, ENDRA had $6.4 million in cash and an accumulated deficit of $96.9 million.
• The company anticipates completing clinical studies for its TAEUS system by late 2024 or early 2025 and submitting a new de novo request to the FDA in the first half of 2025.
• There were significant leadership changes including the resignation of the CEO and CFO, and the appointment of a new acting CEO and CFO.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in raising capital and advancing its technology, it continues to operate at a loss, faces regulatory hurdles, and has experienced significant leadership changes. The material weakness in internal controls is also a concern.

Positives

• The company successfully raised $7.34 million through a public offering in June 2024.
• Research and development expenses decreased, indicating a shift towards commercialization.
• The company is progressing towards a new de novo submission to the FDA for its TAEUS system.
• The company has a cash balance of $6.4 million, providing some runway for operations.

Negatives

• The company continues to operate at a loss, with a net loss of $5.00 million for the first six months of 2024.
• The company has an accumulated deficit of $96.9 million.
• The company has not generated any revenue from its TAEUS technology.
• The company identified a material weakness in its internal controls over financial reporting.
• There were significant leadership changes including the resignation of the CEO and CFO.

Risks

• The company has a history of losses and limited commercial experience.
• The company's ability to continue as a going concern is dependent on securing additional financing.
• There is uncertainty regarding the timing and outcome of the FDA approval process.
• The company faces competition in the medical device industry.
• The company's success depends on market acceptance of its TAEUS technology.
• The company's internal controls over financial reporting are not effective.

Future Outlook

The company anticipates completing clinical studies by late 2024 or early 2025 and submitting a new de novo request to the FDA in the first half of 2025. The company will need to raise additional capital to fund operations.

Management Comments

• Management plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing.
• Management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

Industry Context

The company is developing a non-invasive technology for diagnosing and treating medical conditions, which is a growing trend in the healthcare industry. The company's focus on NAFLD aligns with the increasing prevalence of this condition globally.

Comparison to Industry Standards

• ENDRA's lack of revenue is typical for a pre-commercial stage medical device company.
• The company's R&D spending is consistent with other companies in the medical device sector focused on novel technologies.
• The company's reliance on capital raises is common for companies in this stage of development.
• The company's timeline for FDA approval is within the typical range for medical devices, but subject to potential delays.
• Comparable companies include those developing non-invasive diagnostic technologies, such as FibroScan by Echosens, which is used for liver stiffness measurement, and other companies developing ultrasound-based diagnostic tools.

Management Changes

Corporate Governance

Legal Proceedings

• As of June 30, 2024, there were no legal matters that management believes would have a material effect on the Company's financial position or results of operations.

Related Party Transactions

• The company has a consulting agreement with director Alex Tokman.
• The company has a consulting agreement with PatentVest, a subsidiary of MDB Capital Holdings, LLC, where two of the company's directors are also affiliated.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be affected by the leadership changes and potential restructuring.
• Customers and partners may be impacted by the delays in the FDA approval process.
• Creditors may be concerned about the company's ongoing losses and need for additional financing.

Next Steps

• Complete clinical studies for the TAEUS system.
• Submit a new de novo request to the FDA.
• Continue to seek additional financing.
• Address the material weakness in internal controls.
• Hire a new permanent CEO.

Key Dates

Keywords

TAEUS, FDA approval, Non-alcoholic fatty liver disease, NAFLD, Thermo-Acoustic Enhanced Ultrasound, Medical device, Clinical trials, De novo, Financial results, Capital raise